

**S4 Table.** Risk factors for COVID-19–related mortality in patients with B-cell lymphoma treated with B-cell depleting agents within 1 year prior to COVID-19

	Death (n=12)	Survivor (n=32)	Univariate		Multivariable	
			OR (95% CI)	p-value	aOR (95% CI)	p-value
Age (per 1-year increase)	75 (73-81)	67 (57-74)	1.10 (1.01-1.20)	0.031	1.07 (0.98-1.17)	0.154
Male sex	10 (83.3)	16 (50.0)	5.00 (0.94-26.53)	0.059	7.13 (0.91-55.71)	0.061
BMI	20.7 (19.3-23.6)	24.1 (20.2-26.9)	0.85 (0.71-1.03)	0.096		
Vaccination status						
Fully vaccinated	8 (66.7)	24 (75.0)	0.67 (0.16-2.82)	0.582		
Underlying comorbidities						
HTN	6 (50.0)	10 (31.3)	2.20 (0.57-8.54)	0.255		
DM	1 (8.3)	8 (25.0)	0.27 (0.03-2.46)	0.247		
CKD	0 (0.0)	2 (6.3)	-	0.999		
CVD	0 (0.0)	1 (3.1)	-	> 0.999		
Chronic lung disease	1 (8.3)	1 (3.1)	2.82 (0.16-49.01)	0.477		
ECOG performance status						
0-1	10 (83.3)	32 (100.0)	1.00			
≥ 2	2 (16.7)	0 (0.0)	-	0.999		
B-cell depleting therapy						
RTX	5 (41.7)	26 (81.3)	1.00		1.00	
TCE	7 (58.3)	6 (18.8)	6.07 (1.42-25.89)	0.015	7.48 (1.17-47.85)	0.034
Total duration of TCE or RTX therapy	236 (33-375)	148 (94-546)	1.00 (1.00-1.00)	0.339		
Prior lymphoma therapy						
Autologous stem-cell transplant	0 (0.0)	7 (21.9)	-	0.999		
CAR T-cell therapy	0 (0.0)	1 (3.1)	-	> 0.999		
Bendamustine therapy	7 (58.3)	13 (40.6)	2.05 (0.53-7.87)	0.298		
Lymphoma status						
Response <sup>a)</sup>	8 (80.0)	23 (79.3)	1.00			
Non-response	2 (20.0)	6 (20.7)	0.96 (0.16-5.75)	0.963		
Dominant variant						
Omicron	11 (91.7)	29 (90.6)	1.00			
Delta	1 (8.3)	3 (9.4)	0.88 (0.08-9.37)	0.915		

Values are presented as median (IQR) or number (%). aOR, adjusted odds ratio; BMI, body mass index; CAR, chimeric antigen receptor; CI, confidence interval; CKD, chronic kidney disease; COVID-19, coronavirus disease 2019; CVD, cardiovascular disease; DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; HTN, hypertension; IQR, interquartile range; OR, odds ratio; RTX, rituximab; TCE, T-cell engager. <sup>a)</sup>Include complete or partial response to treatment.